Calidi Biotherapeutics, Inc. (CLDI)Healthcare | Biotechnology | San Diego, United States | NYSE American
1.32 USD
+0.02
(1.538%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 1.32 |
Hot Take ↕ | Aug. 22, 2026, 3:56 a.m. EDT
The immediate outlook is severely clouded by a massive reverse stock split announced for late July 2026, which often signals distress or a desperate attempt to meet listing requirements rather than operational success. Fundamentally, the company is in a precarious state with negative earnings, negative return on equity, and a balance sheet showing significant debt relative to equity. The price history tells a catastrophic story: over the last three years, the investment has lost 99.85% of its value, driven by three consecutive years of double-digit percentage declines, including a nearly 99% drop in the most recent full year. While recent trading shows some volatility, the trend remains firmly downward, and the statistical forecasting models offer very low confidence in any short-term recovery. There is no dividend income to offset these losses, making this a high-risk speculative vehicle with no clear path to capital preservation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.138416 |
| AutoETS | 0.139546 |
| AutoARIMA | 0.160281 |
| AutoTheta | 0.173306 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 7.16 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.345 |
| Excess Kurtosis | -0.89 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 61.985 |
| Market Cap | 3,411,123 |
| Forward P/E | -1.47 |
| Beta | 1.33 |
| Website | https://www.calidibio.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.95075756 |
| Address1 | 4,475 Executive Drive |
| Address2 | Suite 200 |
| All Time High | 26,476.8 |
| All Time Low | 1.25 |
| Ask | 1.31 |
| Ask Size | 500 |
| Average Daily Volume10 Day | 114,460 |
| Average Daily Volume3 Month | 316,102 |
| Average Volume | 316,102 |
| Average Volume10Days | 114,460 |
| Beta | 1.333 |
| Bid | 1.27 |
| Bid Size | 5,000 |
| Book Value | 1.498 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.32 |
| Current Ratio | 1.677 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 1.37 |
| Day Low | 1.28 |
| Debt To Equity | 61.985 |
| Display Name | Calidi Biotherapeutics |
| Ebitda | -16,137,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.08 |
| Enterprise Value | 1,294,497 |
| Eps Forward | -0.9 |
| Eps Trailing Twelve Months | -37.04 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 858 794 9605 |
| Fifty Day Average | 1.8936 |
| Fifty Day Average Change | -0.57359993 |
| Fifty Day Average Change Percent | -0.30291504 |
| Fifty Two Week Change Percent | -95.07576 |
| Fifty Two Week High | 27.84 |
| Fifty Two Week High Change | -26.52 |
| Fifty Two Week High Change Percent | -0.95258623 |
| Fifty Two Week Low | 1.25 |
| Fifty Two Week Low Change | 0.07000005 |
| Fifty Two Week Low Change Percent | 0.056000043 |
| Fifty Two Week Range | 1.25 - 27.84 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,635,773,400,000 |
| Float Shares | 2,564,822 |
| Forward Eps | -0.9 |
| Forward P E | -1.4666668 |
| Free Cashflow | -10,016,875 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 29 |
| Fullday Change | 0.0200001 |
| Fullday Change Percent | 1.53847 |
| Fullday Price | 1.32 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.008719999 |
| Held Percent Institutions | 0.01424 |
| Implied Shares Outstanding | 2,584,184 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,785,456,000 |
| Last Split Factor | 1:16 |
| Long Business Summary | Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California. |
| Long Name | Calidi Biotherapeutics, Inc. |
| Market | us_market |
| Market Cap | 3,411,123 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_572193913 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -23,455,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,359,439 |
| Open | 1.32 |
| Operating Cashflow | -17,751,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 858 794 9600 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 1.32 |
| Post Market Time | 1,787,961,317 |
| Previous Close | 1.3 |
| Price Hint | 4 |
| Price To Book | 0.8811749 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.34 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0200001 |
| Regular Market Change Percent | 1.53847 |
| Regular Market Day High | 1.37 |
| Regular Market Day Low | 1.28 |
| Regular Market Day Range | 1.28 - 1.37 |
| Regular Market Open | 1.32 |
| Regular Market Previous Close | 1.3 |
| Regular Market Price | 1.32 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 51,793 |
| Return On Assets | -1.34786 |
| Return On Equity | -6.72221 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 2,584,184 |
| Shares Percent Shares Out | 0.121199995 |
| Shares Short | 313,261 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 213,839 |
| Short Name | Calidi Biotherapeutics, Inc. |
| Short Percent Of Float | 0.122200005 |
| Short Ratio | 0.73 |
| Source Interval | 15 |
| State | CA |
| Symbol | CLDI |
| Total Cash | 4,071,000 |
| Total Cash Per Share | 1.57 |
| Total Debt | 1,942,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -37.04 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.05868 |
| Two Hundred Day Average Change | -7.7386794 |
| Two Hundred Day Average Change Percent | -0.8542834 |
| Type Disp | Equity |
| Volume | 51,793 |
| Website | https://www.calidibio.com |
| Zip | 92,121 |